This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.
GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The post GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA appeared first on Pharmaceutical Technology.
RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.
The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies. Download the full report to understand what to expect and how to align your strategies for success.
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Moderna ’s investigational mRNA vaccine candidate, mRNA-1345, for respiratory syncytial virus (RSV) in adult patients. The investigational mRNA-1345 vaccine uses the same lipid nanoparticles (LNPs) that are also used in the Moderna Covid-19 vaccines.
As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.
in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments. By Cytiva Thematic.
After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).
To develop a vaccine and then get as many people vaccinated as quickly as possible. Advanced monitoring and analysis technology has enabled more than 13 billion COVID-19 vaccinations to be distributed worldwide to date. In an ever-changing environment, more robust and scalable communications solutions are required.
Oragenics and Inspirevax have signed a license agreement to develop the former’s lead intranasal vaccine candidate for Covid-19, NT-CoV2-1. As part of the exclusive international agreement, Oragenics agreed to pursue the vaccine development with the new BDX301 intranasal mucosal adjuvant of Inspirevax.
Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.
million government grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency that will be used to fuel the company’s vaccine platform, per a 30 May announcement. The company’s prophylactic yellow fever vaccine is part of its plasmid-launched live attenuated virus (PLLAV) platform. AstriVax has received a €2.5
Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.
After a long period of inactivity in RSV vaccine development , two pharmaceutical companies are now approaching regulatory decisions for their RSV vaccines. Both Pfizer and GSK have major approval decisions regarding the use of their RSV vaccines for older adults this May. What incentivises a country to cover a vaccine?
RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.
China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. With this regulatory approval, CSPC Pharmaceutical is claimed to be the first company to receive approval for providing an mRNA vaccine in the country.
Among other things, supply chain optimisation, maintaining access to affordable vaccines, and supporting innovation for unmet clinical needs will be the discussion topics, she adds. Download the full report to understand what to expect and how to align your strategies for success. Please check your email to download the Report.
Pharmaron is receiving a £151 million investment in capital to support the growth of operations in Liverpool, quadrupling production capacity for gene therapy and vaccine components. Download the full report to understand what to expect and how to align your strategies for success. Please check your email to download the Report.
This all requires communication by the pharmacy team between providers, patients, and insurers to get medication to the patient. For instance, a physical location offers the ability to offer vaccinations and filling of same-day needed prescriptions (such as antibiotics, pain medications, etc.) Download Image.
With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.
There is a stark difference in favour of the UK biotech ecosystem in terms of expenses compared to the US biotech ecosystem, and specifically the New England region, says Mark Leuchtenberger, CEO of Oxford-based company SpyBiotech, a vaccine developer that plans to study a human cytomegalovirus infection vaccine in H2 2023.
This method not only prioritizes the participant’s comprehension but also aligns with best practices in health communication that suggests a focused approach can significantly enhance understanding and retention of important information. The importance of using plain language in health communications is well-documented in literature.
Prefilled syringes are increasingly being recognised as the safest method of packaging injectable drugs, and they offer a number of advantages when administering vaccines specifically. Please check your email to download the Whitepaper. Lessons from the Pandemic: Building a Better Prefilled Syringe. By Datwyler. United Kingdom.
Common treatment options for the condition include bladder removal surgery, chemotherapy and/or administration of the BCG vaccine in the bladder. According to GlobalData, Adstiladrin is one of six therapies approved for the treatment of non-muscle invasive bladder cancer in the US, including two BCG vaccines.
The value of real-time data Amid unprecedented instability in lockdown-stricken supply chains, digital transformation company Controlant helped to safely deliver more than 5 billion COVID-19 vaccines. Download the whitepaper on this page to find out more. Download the whitepaper to find out more.
The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg. Poolberg Pharma is deploying AI algorithms on early-stage clinical data to prioritise and reposition vaccine candidates for respiratory syncytial virus. Download the whitepaper to find out more.
This role is great for helping you enhance your communication skills. Telehealth nursing helps you become a better communicator with all types of patients and professionals. Medical assistants need training to administer vaccines. This can be a great way to improve your patient care and communication skills with children.
PM: Lyophilization is widely used in the pharmaceutical and biotech industry for small molecule drug products, vaccines, antibodies, and other biological material. Please check your email to download the eBook. What are the key advantages of this stabilization method? Virgin Islands, U.S. Wallis and Futuna. Western Sahara.
The swift development of COVID-19 vaccines was an unprecedented scientific and collaborative achievement by government, regulators, research institutions, and the pharmaceutical industry. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies. By GlobalData. United Kingdom.
Transgene will be presenting new data at ASCO 2023 for its therapeutic cancer vaccines TG4001, in Phase II study in patients with HPV16-positive anogenital tumours ( NCT03260023 ), and TG4050, Phase I study in head and neck cancers ( NCT04183166 ). Please check your email to download the Report.
Source: GlobalData Pharmaceutical Intelligence Center Clinical trial catalysts In late January, AC Immune released positive interim results from the Phase I/II trial (NCT05462106) studying the company’s vaccine in patients with prodromal Alzheimer’s disease. Please check your email to download the Report.
National Influenza Vaccination Week: December 6-12. Cervical Health Awareness Month | S hare downloadable content from the NCCC and advocate for HPV vaccinations. World Immunization Week | Post a flyer and share a list on social media of your vaccination offerings. . National Diabetes Month. COPD Awareness Month.
The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData.
Bookly : Streamline Appointment Scheduling Bookly is an indispensable tool for pharmacies offering services like vaccinations, health consultations, or medication reviews. With 70,000 active downloads, it is clear to see why businesses around the world love this feature.
During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry. While production volumes have now fallen, future vaccine demand is hard to predict, as booster shots could be needed at any point to control emerging variants.
The Association of the British Pharmaceutical Industry (ABPI) also states that “the use of animals in medical research has played and continues to play an essential role in the development of new medicines and vaccines”. The topic of animal testing remains a fiercely contentious topic in the public eye.
The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. Controlant’s real-time visibility platform and command center is already transforming vaccine distribution by meticulously tracking shipments from origin sites to vaccination hubs.
With two historic FDA approvals for RSV vaccines in the last two months, this issue’s lead interview addresses the pertinent question of access— how to ensure eligible individuals across the world get this vaccine. Download the full report to understand what to expect and how to align your strategies for success.
Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. Research into genetic medicines like mRNA vaccines and gene therapies, as well as gene-editing treatments and novel cancer therapies, have driven increased demand for DNA.
SB: Over the past 25 years, Recombinant Insulin supplementation has become standardised in the production of monoclonal antibodies as well as virus vaccines. For more information and detailed application studies concerning the use of Recombinant Insulin in biomanufacturing, please download the new eBook below.
The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. Controlant’s real-time visibility platform and command center is already transforming vaccine distribution by meticulously tracking shipments from origin sites to vaccination hubs.
Its development pipeline comprises chimeric antigen receptor (CAR)-T cell therapies, CD47 immune checkpoint inhibitor and Guanylyl Cyclase C (GCC) cancer vaccine. The GCC Vaccine is being analysed in Phase II clinical trials. By Cytiva Thematic.
The increase in the production of biological drugs such as vaccines, gene and cell therapies, and monoclonal antibodies, is increasing the volume of injectable drug products in the global healthcare market.
Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content